Peri-transplant Treatment with Ceftaroline in Kidney Transplant Recipients at Risk of Donor-derived MRSA Infections: A Case Series













Abstract
579 3546
Peri-transplant Treatment with Ceftaroline in Kidney Transplant Recipients at Risk of Donor-derived MRSA Infections: A Case Seriesby
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() Abstract
The rising prevalence of MDR pathogens has a significant impact on the recipients' outcome, as this increases the risk of graft complications and makes the management of the peri-transplant phase more difficult. Among the different MDR germs, Methicillin-resistant Staphylococcus aureus (MRSA) represents one of the most frequently isolated pathogens. We report for the first time the off-label use of Ceftaroline in six kidney transplant recipients with donor peritransplantation MRSA bacteremia at the Division of Kidn [...] 579 3546 |
Utility of MEST and MEST-C Scoring in IgA Nephropathy in Kidney Transplantation: A Mini ReviewAbstract
IgAN is a major cause of end-stage kidney disease (ESKD) leading to kidney transplantation in a significant proportion of patients. However, its recurrence in transplanted kidneys can lead to graft loss. The rate of graft loss attributable to IgAN after transplantation is variably reported in different retrospective cohorts. Previous reports describe recurrence rates of 22-58% with a 1.3% to 16% rate of graft loss. Accurate diagnosis and prediction of graft loss are important for planning effective therapies to imp [...] 505 3462 |
Multimodal Pain Management of Liver Transplantation: What Is New?Abstract
Liver transplantation (LT) is a life-saving treatment representing the only viable option for patients suffering from end-stage liver disease (ESLD) or acute liver failure. Patients who undergo LT require a multidisciplinary approach to postoperative pain management. However, pain management in this context is often inadequately explored. Limited options exist for proper pain control in patients with hepatic failure, mainly due to the increased risk of kidney and multi-organ failure. In LT candidates, specific anal [...] 818 6416 |
Lung Transplantation: Selection of CandidatesAbstract
Lung transplantation is a last-resort treatment option for patients with end stage lung disease. The procedure is being performed more frequently and scientific advances continue to be made, but the median post-transplant survival is far shorter than other solid organ transplant recipients. Candidate selection is a resource intensive process that attempts to balance risks of the procedure with the benefits of much higher quality of life. Transplant centers must weigh disease specific considerations, medical comorbi [...] 596 3814 |
A Urinary Proteomics Approach to Predict Treatment Response in Acute Antibody-Mediated Rejectionby
![]() ![]() ![]() ![]() ![]() ![]() ![]() Abstract
Acute antibody-mediated rejection (AMR) is a severe complication affecting kidney allografts' long-term survival. Timely detection and appropriate treatment of AMR are crucial for improving graft outcomes. This study aimed to discover non-invasive urinary biomarkers that can predict the response to therapy in patients with AMR. Materials and Methods: In this case-control study, urine samples from 21 biopsy-proven AMR patients underwent proteomics using label-free quantification. The patients were divided into two g [...] 532 3553 |
Oral Versus Intravenous Anti-CMV Preemptive Strategies in Allogeneic Stem Cell Transplant Patients with CMV Reactivation: Experience from the National Center of Bone Marrow Transplantation, Tunis, Tunisiaby
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() Abstract
Cytomegalovirus (CMV) infection is a common and severe complication following allogeneic stem cell transplantation (ASCT) and requires effective preemptive antiviral therapy. Both oral and intravenous (IV) antiviral agents effectively reduce CMV viral load and achieve viral clearance. Studies comparing oral and IV anti-CMV preemptive treatment in ASCT patients with CMV reactivation showed a potential difference in treatment response and safety profiles between the two administration routes. We retrospectively compa [...] 469 4204 |
A Rare and Complex Case of Multifactorial Thrombotic Microangiopathy in A Kidney Transplant Recipient: Interplay Between Antibody Mediated Rejection, Tacrolimus Toxicity, Cytomegalovirus Disease and BNT162b2mRNA VaccineAbstract
Thrombotic microangiopathy (TMA) in kidney transplant recipients is uncommon and difficult to manage, often with poor graft outcomes [1]. This is a complex and interesting case of an older, highly sensitised kidney transplant recipient who presented with de novo post-transplant TMA in the setting of antibody mediated rejection (ABMR), with other drivers being tacrolimus toxicity, cytomegalovirus (CMV) infection and anti-SARS-CoV-2 BNT162b2 mRNA vaccination. This led to rapid, irrecoverable graft loss. 76-year-old f [...] 550 3936 |
Lung Transplantation for COVID-19 Related Lung Disease: A Follow-Up Study of Outcomes from a Medium-Size Lung Transplant Programdby
![]() ![]() ![]() ![]() ![]() ![]() Abstract
In the United States of America, COVID-19 acute respiratory distress syndrome (ARDS) and post-COVID pulmonary fibrosis (PCPF) are raising indications for lung transplant (LT). Another indication for LT is underlying fibrosis with SARS-CoV-2 induced interstitial lung disease exacerbation or rapid progressing fibrosis. Only a few centers have reported on their long-term outcomes after LT for COVID-19. Single center retrospective chart review of patients transplanted for COVID-19 related lung disease. The Henry Ford H [...] 592 4021 |
BK Virus Infection and Its Management in Renal Transplantation: An Updateby
![]() ![]() ![]() ![]() ![]() ![]() Abstract
BK virus (BKV) is a common opportunistic pathogen in kidney transplant recipients and one of the most challenging causes of allograft dysfunction and loss. Although over-immunosuppression remains the primary risk factor for BKV infection after transplantation, male gender, older recipient age, prior rejection episodes, degree of human leukocyte antigen mismatching, prolonged cold ischemia time, BK virus serostatus and ureteral stent placement have all been implicated as risk factors. Routine screening post-renal tr [...] 712 6124 |
Identification of Potential Predictive and Diagnostic Urinary Biomarkers for Acute Rejection in Renal Transplant Recipients: A Proteomics Studyby
![]() ![]() ![]() ![]() ![]() ![]() ![]() Abstract
Acute rejection (AR) is one of the main predictors of long-term survival of allograft. The development of noninvasive diagnostic biomarkers of AR is an unmet need for the timely detection. This study aimed to identify novel detective biomarkers of AR by analyzing the urine proteome profile of transplant patients. Forty-two transplant patients including 30 biopsy-proven AR patients (including antibody and T-cell mediated rejection) and 12 transplant patients with stable renal function (control group) were enrolled. [...] 573 4277 |
TOP